Treggiari, E, Ressel, L ORCID: 0000-0002-6614-1223, Polton, GA, Benoit, J, Desmas, I and Blackwood, L
(2017)
Clinical outcome, PDGFR beta and KIT expression in feline histiocytic disorders: a multicentre study.
VETERINARY AND COMPARATIVE ONCOLOGY, 15 (1).
pp. 65-77.
This is the latest version of this item.
![]() |
Text
FelineHistiocyticDiseaseFINAL251014.pdf - Unspecified Access to this file is embargoed until Unspecified. Download (1MB) |
Abstract
Information about histiocytic disease in cats is limited. The aim of this study was to document clinical findings and outcome in feline histiocytic disorders, and characterize the expression of PDGFRβ and KIT in order to identify potential treatment targets. Morphologically diagnosed feline histiocytic tumours were reviewed and characterized by immunohistochemistry (IHC). Five cases of feline progressive histiocytosis (FPH), eight histiocytic sarcomas (HS) and two haemophagocytic histiocytic sarcomas (HaeHS) were confirmed. PDGFRβ was variably positive in most histiocytic cases, while KIT was negative in all. Clinical presentation, treatment and outcome were also evaluated. Partial responses were recorded in measurable disease with tyrosine kinase inhibitors and lomustine, and radiotherapy achieved long-term control in some cases. Survival times were shortest in HaeHS and disseminated disease. PDGFRβ, but not KIT, may represent a therapeutic target in feline histiocytic disorders but more studies are needed to investigate other potential treatment targets.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | cats, chemotherapy, histiocytic, KIT, PDGFR, Radiotherapy |
Subjects: | ?? RZ ?? |
Depositing User: | Symplectic Admin |
Date Deposited: | 29 Jul 2015 10:02 |
Last Modified: | 16 Dec 2022 01:36 |
DOI: | 10.1111/vco.12142 |
Related URLs: | |
URI: | https://livrepository.liverpool.ac.uk/id/eprint/2018105 |
Available Versions of this Item
- Clinical outcome, PDGFR beta and KIT expression in feline histiocytic disorders: a multicentre study. (deposited 29 Jul 2015 10:02) [Currently Displayed]